FDA Approves Crizanlizumab, A New Drug For Sickle Cell Disease

Novartis will have the go-ahead to begin marketing Adakveo, the first targeted therapy for sickle cell disease.

Source: Forbes.com Healthcare News - November 17, 2019 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news